Table 1. Demographic and tumor characteristics of ever-screened and never-screened cervical cancer patients in the National Cancer Screening Program.
| Characteristics | Matched (n=9,424) | Un-matched (n=18,388) | |||||
|---|---|---|---|---|---|---|---|
| Never (n=4,712) | Ever (n=4,712) | p-value | Never (n=5,103) | Ever (n=13,285) | p-value | ||
| Age at diagnosis (yr) | 1.00 | <0.01 | |||||
| 30–39 | 2,161 (45.86) | 1,210 (25.68) | 2,475 (48.50) | 2,892 (21.77) | |||
| 40–49 | 1,210 (25.68) | 588 (12.48) | 1,210 (23.71) | 4,483 (33.74) | |||
| 50–59 | 588 (12.48) | 281 (5.96) | 588 (11.52) | 2,783 (20.95) | |||
| 60–69 | 281 (5.96) | 291 (6.18) | 281 (5.51) | 1,715 (12.91) | |||
| 70–79 | 291 (6.18) | 181 (3.84) | 291 (5.70) | 1,145 (8.62) | |||
| ≥80 | 181 (3.84) | 1,210 (25.68) | 258 (5.06) | 267 (2.01) | |||
| Socioeconomic status | 1.00 | 0.04 | |||||
| NHI (premium >50%) | 1,844 (39.13) | 1,844 (39.13) | 1,943 (38.08) | 5,308 (39.95) | |||
| NHI (premium ≤50%) | 2,711 (57.53) | 2,711 (57.53) | 2,987 (58.53) | 7,446 (56.05) | |||
| MAP recipients | 157 (3.33) | 157 (3.33) | 173 (3.39) | 531 (4.00) | |||
| Tumor stage* | <0.01 | <0.01 | |||||
| CIS | 2,581 (54.78) | 3,382 (71.77) | 2,819 (55.24) | 8,847 (66.59) | |||
| Localized | 931 (19.76) | 879 (18.65) | 996 (19.52) | 2,715 (20.44) | |||
| Regional | 784 (16.64) | 323 (6.85) | 821 (16.09) | 1,178 (8.87) | |||
| Distant | 278 (5.90) | 50 (1.06) | 307 (6.02) | 286 (2.15) | |||
| Unknown | 138 (2.93) | 78 (1.66) | 160 (3.14) | 259 (1.95) | |||
Values are presented as number (%).
CIS, carcinoma in situ; MAP, Medical Aid Program; NHI, National Health Insurance.
*Tumor stage definitions adapted from the Surveillance, Epidemiology, and End Results Cancer Statistics Review: CIS, neoplasm confined to the cervix without invading the surrounding stroma; localized, neoplasm confined entirely to the cervix without serosal involvement; regional, neoplasm that extends beyond the limits of the cervix of uteri, invading the surrounding tissue; distant, neoplasm that spreads to parts of the body remote from the primary tumor; and unknown, neoplasm with insufficient or unavailable information to assign a stage.